An open-label, one-way crossover third phase III study of ALN-AT3 in subjects with severe haemophilia A or B.

Trial Profile

An open-label, one-way crossover third phase III study of ALN-AT3 in subjects with severe haemophilia A or B.

Suspended
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Fitusiran (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-PPX
  • Most Recent Events

    • 09 Nov 2017 According to an Alnylam Pharmaceuticals media release, alignment reached with FDA on amended safety measures and risk mitigation strategy to enable resumption of fitusiran clinical program. Reinitiation of dosing will be announced around year end.
    • 09 Nov 2017 According to an Alnylam Pharmaceuticals media release, after a Type A meeting with the U.S. Food and Drug Administration (FDA), the FDA will now consider removal of the clinical hold upon final review of the amended protocols and other trial materials.
    • 07 Sep 2017 According to an Alnylam Pharmaceuticals media release, based on overall consideration of fitusirans benefit-risk profile, the company expects to resume dosing upon agreement with global regulatory authorities and with appropriate protocol amendments in place for enhanced patient safety monitoring, in all of its clinical studies (Phase 2 OLE and ATLAS Phase 3 program) as soon as possible, potentially as early as late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top